{"id":230949,"date":"2017-07-29T04:50:20","date_gmt":"2017-07-29T08:50:20","guid":{"rendered":"http:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/uncategorized\/insilico-medicine-signs-deal-to-advance-use-of-ai-in-discovering-new-drugs-technical-ly-baltimore.php"},"modified":"2017-07-29T04:50:20","modified_gmt":"2017-07-29T08:50:20","slug":"insilico-medicine-signs-deal-to-advance-use-of-ai-in-discovering-new-drugs-technical-ly-baltimore","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/medicine\/insilico-medicine-signs-deal-to-advance-use-of-ai-in-discovering-new-drugs-technical-ly-baltimore.php","title":{"rendered":"Insilico Medicine signs deal to advance use of AI in discovering new drugs &#8211; Technical.ly Baltimore"},"content":{"rendered":"<p><p>    Insilico Medicine has a new agreement with a    British investors biotech company that will result in the    companys platform being used to develop new compounds for use    in drugs that treat aging and age-related diseases.  <\/p>\n<p>    The startup, which is based at ETCs Eastern campus, signed a    deal with Juvenescence    AI,according to a press    release. As a result, the two companies have a drug development    agreement under the title Juvenescence AI    Limited. Along with the deal, Juvenescence made an    investment into Insilico Medicine. The amount was not    disclosed.  <\/p>\n<p>    Insilico applies machine learning to the process of drug    discovery. As founderAlex Zhavoronkov    told Technical.ly Baltimore,    the companys platform is designed to use deep learning    techniques to analyze how a compound will affect cells. This    process is currently determined through trials.  <\/p>\n<p>    We are excited by the potential for AI to streamline the    longest and most costly portions of the drug development cycle:    clinical trials, Juvenescence Chairman Jim    Mellon said in a statement. With Insilico Medicines    help, we hope Juvenescence AI will both develop therapeutics    that treat the diseases that plague all of us as we age and    eventually treat the aging process itself.  <\/p>\n<p>    With the deal, Juvenescence AI will license several compound    families from Insilico.  <\/p>\n<p>  Stephen Babcock is Market Editor for Technical.ly Baltimore and  Technical.ly DC. A graduate of Northeastern University, he moved  to Baltimore following stints in New Orleans and Rio Arriba  County, New Mexico. His work has appeared in The New York Times,  Baltimore Fishbowl, NOLA Defender, NOLA.com\/The Times-Picayune  and the Rio Grande Sun.<\/p>\n<p><!-- Auto Generated --><\/p>\n<p>View post:<\/p>\n<p><a target=\"_blank\" href=\"https:\/\/technical.ly\/baltimore\/2017\/07\/28\/insilico-medicine-juvenescence\/\" title=\"Insilico Medicine signs deal to advance use of AI in discovering new drugs - Technical.ly Baltimore\">Insilico Medicine signs deal to advance use of AI in discovering new drugs - Technical.ly Baltimore<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> Insilico Medicine has a new agreement with a British investors biotech company that will result in the companys platform being used to develop new compounds for use in drugs that treat aging and age-related diseases.  <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/medicine\/insilico-medicine-signs-deal-to-advance-use-of-ai-in-discovering-new-drugs-technical-ly-baltimore.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[35],"tags":[],"class_list":["post-230949","post","type-post","status-publish","format-standard","hentry","category-medicine"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/230949"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=230949"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/230949\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=230949"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=230949"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=230949"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}